IN2014MN00357A - - Google Patents

Info

Publication number
IN2014MN00357A
IN2014MN00357A IN357MUN2014A IN2014MN00357A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A IN 357MUN2014 A IN357MUN2014 A IN 357MUN2014A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A
Authority
IN
India
Prior art keywords
hydrophobic
peptides
peptide
yrfli
irfli
Prior art date
Application number
Other languages
English (en)
Inventor
Michael John Gait
Andrey Alexandrovich Arzumanov
Amer F Saleh
Matthew J A Wood
Corinne Betts
Taeyoung Koo
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1115014.1A external-priority patent/GB201115014D0/en
Priority claimed from GBGB1211740.4A external-priority patent/GB201211740D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of IN2014MN00357A publication Critical patent/IN2014MN00357A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
IN357MUN2014 2011-08-30 2012-08-29 IN2014MN00357A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161528804P 2011-08-30 2011-08-30
GBGB1115014.1A GB201115014D0 (en) 2011-08-30 2011-08-30 Peptides
GBGB1211740.4A GB201211740D0 (en) 2012-07-03 2012-07-03 Peptides
PCT/GB2012/052116 WO2013030569A2 (en) 2011-08-30 2012-08-29 Peptides

Publications (1)

Publication Number Publication Date
IN2014MN00357A true IN2014MN00357A (he) 2015-06-19

Family

ID=47756980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN357MUN2014 IN2014MN00357A (he) 2011-08-30 2012-08-29

Country Status (10)

Country Link
US (1) US9302014B2 (he)
EP (1) EP2751128B1 (he)
JP (1) JP6077543B2 (he)
CN (1) CN103998458B (he)
AU (1) AU2012300633B2 (he)
BR (1) BR112014004902B1 (he)
CA (1) CA2846218C (he)
ES (1) ES2876939T3 (he)
IN (1) IN2014MN00357A (he)
WO (1) WO2013030569A2 (he)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160106175A (ko) 2014-01-13 2016-09-09 버그 엘엘씨 에놀라아제 1 조성물들 및 이의 용도
US20170197011A1 (en) * 2014-06-06 2017-07-13 Vivoscript, Inc. Methods for repairing cartilage damage
CN104645317B (zh) * 2015-01-28 2020-04-17 中国科学院天津工业生物技术研究所 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3010599A1 (en) * 2016-01-06 2017-07-13 D. Travis Wilson Methods and compositions for the prevention and treatment of duchenne muscular dystrophy
EA201892467A1 (ru) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Олигонуклеотидные аналоги, нацеленные на lmna человека
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
IL301091A (he) 2016-07-05 2023-05-01 Biomarin Tech Bv אוליגונוקליאוטידים המכילים שלד ביציקלי ושימוש בהם לטיפול במחלות גנטיות
WO2018150196A1 (en) * 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Nrf2路徑的新穎化合物
WO2019070962A1 (en) * 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
EP3784248A4 (en) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATE FOR MUSCLE DYSTROPHY
WO2019226651A1 (en) * 2018-05-22 2019-11-28 Children's Medical Center Corporation Nanoparticles for treatment of choroidal neovascularization and other indications
GB201812972D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
US20220125934A1 (en) 2018-12-07 2022-04-28 Oxford University Innovation Limited Linkers
CN113660938A (zh) * 2019-01-30 2021-11-16 国立研究开发法人国立精神·神经医疗研究中心 核酸递送复合物
GB201911403D0 (en) * 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
AU2022312170A1 (en) 2021-07-16 2024-02-08 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide for inhibiting quaking activity
JPWO2023026994A1 (he) 2021-08-21 2023-03-02
WO2023214373A2 (en) 2022-05-06 2023-11-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide
GB202216207D0 (en) * 2022-11-01 2022-12-14 Univ Oxford Innovation Ltd Shortened cell-penetrating peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20090099066A1 (en) 2007-06-29 2009-04-16 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
US8575305B2 (en) * 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds

Also Published As

Publication number Publication date
JP2014526238A (ja) 2014-10-06
CN103998458B (zh) 2018-10-09
US20140342992A1 (en) 2014-11-20
BR112014004902A2 (pt) 2017-07-04
JP6077543B2 (ja) 2017-02-08
WO2013030569A2 (en) 2013-03-07
US9302014B2 (en) 2016-04-05
AU2012300633A8 (en) 2014-05-29
WO2013030569A3 (en) 2013-06-13
CA2846218C (en) 2020-09-01
CN103998458A (zh) 2014-08-20
EP2751128B1 (en) 2021-03-03
AU2012300633A1 (en) 2014-03-06
AU2012300633B2 (en) 2017-04-27
ES2876939T3 (es) 2021-11-15
BR112014004902B1 (pt) 2022-02-08
EP2751128A2 (en) 2014-07-09
CA2846218A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
IN2014MN00357A (he)
NZ704192A (en) Cell-penetrating peptides and uses therof
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
MX359411B (es) Complementación funcional bipartita inducida por antígenos, dual.
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
EP4286400A3 (en) Improved peptide pharmaceuticals
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
WO2012012352A3 (en) Modified peptides and proteins
JP2014224126A5 (he)
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
MX2009013325A (es) Transfeccion y transduccion de plantas con base en nano acarreadores.
Kawaguchi et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking
WO2014134509A3 (en) Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes
MX2009007261A (es) Vacuna de peptido foxp3.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
WO2011048503A3 (en) Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
IN2014DN09963A (he)
MX2010005816A (es) Epítopos de péptido de stat3.
MX365599B (es) Moleculas de transporte especificas de proteoglicano c4s.
MY151307A (en) Peptides having antimicrobial activity
NZ603379A (en) Ect2 peptides and vaccines including the same
JP2011512364A5 (he)
WO2013162948A3 (en) Fluorous peptide microarray, detection process using a fluorous peptide microarray, and process of forming a fluorous peptide microarray